Anifrolumab在成人系统性红斑狼疮中的长期安全性与疗效:II期开放标签扩展研究结果
该3年多国开放标签扩展研究纳入完成MUSE IIb期随机对照试验的246例中重度SLE成人患者中的218例(88.6%),评估anifrolumab长期安全性。结果显示不良事件频率与模式与1年治疗一致,无新安全信号,SLEDAI-2K改善持续3年,SDI与SF-36稳定。
要点
- 218例入组开放标签扩展,139例(63.8%)完成3年治疗,6.9%因不良事件停药。
- 3年严重不良事件与特别关注不良事件频率和模式与RCT 1年治疗一致,无新安全信号。
- SLEDAI-2K改善持续3年,SDI与SF-36评分保持稳定。
核心结论
- 长期anifrolumab治疗显示可接受的安全性,并持续改善SLE疾病活动度、健康相关生活质量及血清学指标。
研究设计与样本
- 3年多国开放标签扩展研究,纳入完成MUSE IIb期随机对照试验48周治疗及12周随访的成人中重度SLE患者。
- 患者初始接受anifrolumab 1,000 mg静脉注射每4周一次,后基于MUSE试验获益/风险特征改为300 mg每4周一次。
- 共218例患者入组开放标签扩展研究,其中139例(63.8%)完成3年治疗。
主要发现
- 开放标签扩展治疗第一年约69.7%患者报告至少1例不良事件。
- 3年严重不良事件与特别关注不良事件的频率和模式与RCT 1年治疗报告一致。
- 6.9%患者因不良事件终止治疗,未发现新安全信号。
- SLEDAI-2K改善持续3年,SDI与SF-36评分保持稳定。
- IFN-high人群中I型干扰素基因特征中和维持,C3、C4及抗双链DNA呈持续改善趋势。
临床怎么用
- 长期使用anifrolumab治疗中重度SLE患者时,安全性特征与短期治疗一致,可支持持续治疗决策。
- 治疗期间应监测不良事件,尤其关注严重不良事件与特别关注不良事件,但无需因新安全信号调整监测策略。
局限性
- 本研究为开放标签扩展研究,无对照组,存在选择偏倚可能。
- 完成3年治疗的患者比例有限(63.8%),长期数据需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate long-term safety and tolerability of anifrolumab, a human monoclonal antibody to the type I interferon (IFN) receptor subunit 1, in patients with moderate-to-severe systemic lupus erythematosus (SLE). METHODS: This 3-year, multinational, open-label extension study included adult patients who completed treatment (48 weeks of anifrolumab or placebo; 12-week follow-up) in the MUSE phase IIb randomized controlled trial (RCT). Patients initially received 1,000 mg of anifrolumab intravenously every 4 weeks, which was reduced to 300 mg every 4 weeks based on the benefit/risk profile established in the MUSE trial. Adverse events (AEs) were assessed monthly. Exploratory end points included the SLE Disease Activity Index 2000 (SLEDAI-2K), Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI), pharmacodynamics, and health-related quality of life (HRQoL). RESULTS: Of the 246 patients who completed the RCT, 218 (88.6%) enrolled in the open-label extension study, of which 139 (63.8%) completed 3 years of treatment. Approximately 69.7% of patients reported ≥1 AE during the first year of open-label extension treatment. Frequency and patterns of serious AEs and AEs of special interest over 3 years were consistent with those reported for 1 year of treatment in the RCT. Few patients (6.9%) discontinued treatment due to AEs. No new safety signals were identified. Improvement in the SLEDAI-2K was sustained over 3 years. SDI and Short Form 36 health survey scores remained stable. Neutralization of type I IFN gene signatures was maintained in the IFN-high population, and C3, C4, and anti-double-stranded DNA showed trends toward sustained improvement. CONCLUSION: Long-term anifrolumab treatment demonstrates an acceptable safety profile with sustained improvement in SLE disease activity, HRQoL, and serologic measures.
引用
- Chatham WW, Furie R, Saxena A, et al. Long-Term Safety and Efficacy of Anifrolumab in Adults With Systemic Lupus Erythematosus: Results of a Phase II Open-Label Extension Study. Arthritis Rheumatol. 2021. PMID: 33225631. doi:10.1002/art.41598
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。